يحاول ذهب - حر
Integrated research campuses: Future of Hyderabad's life sciences industry
March 2025
|Express Pharma
Vishal Goel, MD, RX Propellant outlines how transitioning from isolated industrial clusters to integrated research campuses can drive collaboration, accelerate commercialisation, reduce infrastructure costs, and enhance sustainability
Hyderabad leads in bulk drug manufacturing, advanced biopharma research, and vaccine innovation, serving as the base for renowned international players. The life sciences ecosystem in the city has expanded significantly to include contract research organisations (CROs), contract development and manufacturing organisations (CD-MOs), and medical device manufacturing. However, this growth is still fragmented. Specialised clusters like the Genome Valley and the Medical Devices Park have attracted investment and strengthened supply chains, but they function primarily as co-located industrial zones rather than fully integrated ecosystems where academia, startups, and industry interact seamlessly. Only 12 per cent of Genome Valley’s operations, 18 per cent in Patancheruvu, and 23 per cent in Uppal-Nacharam integrate both R&D and manufacturing, highlighting the need for more connected research environments. The lack of shared R&D infrastructure, real-time industry-academia collaboration, and integrated regulatory pathways lead to inefficiencies in translating research into commercial applications. Additionally, entrepreneurs face challenges in accessing capital while global competition for life sciences investments continues to intensify, making it imperative for Hyderabad to create a more cohesive and innovation-driven ecosystem.
Transitioning from cluster-based models to integrated research campuses could bridge these gaps. Unlike industrial clusters, which focus on sector-specific co-location, integrated campuses create a collaborative environment where research institutions, academia, and industry converge. These campuses foster a multi-disciplinary ecosystem where pharma and biotech firms engage with universities, leveraging shared research infrastructure, joint innovation programs, and industry-driven training to accelerate commercialisation and scientific breakthroughs.
هذه القصة من طبعة March 2025 من Express Pharma.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Express Pharma
Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025
Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025
Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025
Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025
Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025
Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025
Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025
Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025
Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025
Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size

